Sanofi
Analysis summary
moralscore.orgPremier groupe pharmaceutique européen, Sanofi a réalisé 41,1 milliards d'euros de CA en 2024 (+11,3%). Spécialisé dans les médicaments et les vaccins (Dupixent, Beyfortus), Sanofi poursuit une transformation stratégique majeure dont la cession de sa division grand public Opella. Le groupe investit 120 millions dans une nouvelle unité R&D Vaccins. Des critiques portent sur la compétitivité des prix dans l'accès aux médicaments et sur les pratiques fiscales dans certaines juridictions.
Risk level
Several dimensions are poor. Risk of fines, scandal or boycott is elevated. Caution advised.
Detailed risk analysis
Long red bar = high risk on this dimension. Short green bar = solid dimension.
Environmental impact: CO₂ emissions, waste management, water use, climate commitments.
Tax and societal contribution: paying taxes where revenues are generated, philanthropy, local commitments.
Governance: executive pay, board independence, financial transparency, shareholding structure.
Responsible innovation: R&D, beneficial new uses, positive disruption in its market.
Working conditions: fair pay, workplace safety, social dialogue, turnover, wellbeing.
Technology impact: automation, surveillance, digital dependency, ethical AI practices.
Partner fairness: supplier treatment, payment terms, negotiating power, subcontracting practices.
Personal data: collection, storage, customer data use, GDPR compliance, security breaches.
Product/service quality: reliability, user safety, customer satisfaction, recall management.
Price competitiveness: affordability for consumers, pricing practices, cost transparency.
Score computed from the 10 dimensions above (weighted average). Source: CSR reports, court decisions, business press and salary surveys.
Financial data
Source: Yahoo Finance
Updated 18/03/2026, 00:03
- Favourites & Custom lists
- PDF / CSV Export
- Portfolio analysis
- Risk level alerts
- API Access